Stock Market News·2025-12-09 13:08Pharmaceutical Innovations and Regulatory Submissions - Eli Lilly's drug Jaypirca (pirtobrutinib) achieved an 80% risk reduction in progression or death for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients in the Phase 3 BRUIN CLL-313 trial, marking a significant advancement in cancer therapy [2][7] - Johnson & Johnson submitted a supplemental Biologics License Application (sBLA) for the combination of Tecvayli and Darzalex for treating relapsed/refractory multiple myeloma (RRMM) [3][7] Global Market Forecasts and AI Sector Deals - JPMorgan projects emerging equities to outperform developed markets in 2026, driven by a weaker or stable U.S. dollar, and identifies Chinese AI stocks as more affordable compared to U.S. counterparts, indicating potential investment opportunities [4][7] - Anthropic and Accenture announced a partnership aimed at providing advanced AI solutions to business clients [5][7] Consumer Spending Trends and Economic Commentary - Walmart's CEO Doug McMillon highlighted ongoing financial pressure on lower-income consumers despite low single-digit inflation, attributing it to cumulative price increases over the years [6][7] Geopolitical and Monetary Policy Updates - The Swiss National Bank is expected to maintain its main interest rate at 0%, but there are speculations that potential U.S. tariffs could lead to negative interest rates in the future [9][7]